Added to YB: 2024-11-11
Pitch date: 2024-11-09
NVO [bullish]
Novo Nordisk A/S
-53.33%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 107.52
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
Novo Nordisk A/S - $NVO
NVO: Oversold (RSI ~30) with DKK870 FVE. CFO projects high teens 2025 sales growth. Wide moat from innovation: CagriSema, oral semaglutide, comorbidity trials. Bears exaggerate competition; bulls overestimate pricing. Pipeline strength (OASIS, SOUL, FOCUS, STRIDE) maintains leadership. Cheap at current levels.
Read full article (3 min)